BR112013023354A2 - vacina para rinite equina - Google Patents

vacina para rinite equina

Info

Publication number
BR112013023354A2
BR112013023354A2 BR112013023354A BR112013023354A BR112013023354A2 BR 112013023354 A2 BR112013023354 A2 BR 112013023354A2 BR 112013023354 A BR112013023354 A BR 112013023354A BR 112013023354 A BR112013023354 A BR 112013023354A BR 112013023354 A2 BR112013023354 A2 BR 112013023354A2
Authority
BR
Brazil
Prior art keywords
equine rhinitis
equine
vaccine
rhinitis vaccine
compositions
Prior art date
Application number
BR112013023354A
Other languages
English (en)
Other versions
BR112013023354B1 (pt
Inventor
Andres Diaz-Mendez
Kristina J Hennessy
Laurent Viel
Phillip Wayne Hayes
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Priority to BR122019023542-2A priority Critical patent/BR122019023542B1/pt
Publication of BR112013023354A2 publication Critical patent/BR112013023354A2/pt
Publication of BR112013023354B1 publication Critical patent/BR112013023354B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

resumo patente de invenção: "vacina para rinite equina". a presente invenção refere-se a composições imunogênicas contra o vírus da rinite equina, particularmente, o vírus da rinite equina a e b, e métodos para a sua utilização e preparação. as composições imunogênicas, em modalidades suplentes também incluem outros patógenos equinos.
BR112013023354-0A 2011-03-14 2012-03-12 Composição imunogênica compreendendo cepas de vírus da rinite equina a (erav) e seu método de produção BR112013023354B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019023542-2A BR122019023542B1 (pt) 2011-03-14 2012-03-12 Composição imunogênica compreendendo uma ou mais cepas de vírus da rinite equina b (erbv) inativado e seu método de preparação

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161452390P 2011-03-14 2011-03-14
US61/452,390 2011-03-14
US201161510226P 2011-07-21 2011-07-21
US61/510,226 2011-07-21
PCT/US2012/028706 WO2012125525A2 (en) 2011-03-14 2012-03-12 Equine rhinitis vaccine

Publications (2)

Publication Number Publication Date
BR112013023354A2 true BR112013023354A2 (pt) 2016-12-06
BR112013023354B1 BR112013023354B1 (pt) 2022-02-15

Family

ID=45876924

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019023542-2A BR122019023542B1 (pt) 2011-03-14 2012-03-12 Composição imunogênica compreendendo uma ou mais cepas de vírus da rinite equina b (erbv) inativado e seu método de preparação
BR112013023354-0A BR112013023354B1 (pt) 2011-03-14 2012-03-12 Composição imunogênica compreendendo cepas de vírus da rinite equina a (erav) e seu método de produção

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122019023542-2A BR122019023542B1 (pt) 2011-03-14 2012-03-12 Composição imunogênica compreendendo uma ou mais cepas de vírus da rinite equina b (erbv) inativado e seu método de preparação

Country Status (12)

Country Link
US (1) US9187730B2 (pt)
EP (2) EP2772266B1 (pt)
AR (1) AR085800A1 (pt)
AU (2) AU2012229192B2 (pt)
BR (2) BR122019023542B1 (pt)
CA (2) CA3018230A1 (pt)
ES (2) ES2748555T3 (pt)
MA (1) MA35303B1 (pt)
MX (1) MX350718B (pt)
NZ (1) NZ614147A (pt)
TW (1) TW201300537A (pt)
WO (1) WO2012125525A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2772266B1 (en) 2011-03-14 2019-07-31 Boehringer Ingelheim Animal Health USA Inc. Equine Rhinitis vaccine
CA2967532A1 (en) 2014-11-24 2016-06-02 Intervet International B.V. Inactivated equine influenza virus vaccines
US10064930B2 (en) * 2015-01-16 2018-09-04 Boehringer-Ingelheim Vermedica, Inc. Immunogenic compositions and methods for pigeon fever

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
AUPN720195A0 (en) 1995-12-18 1996-01-18 University Of Melbourne, The Equine rhinovirus 1 proteins
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
CA2438692C (en) 2001-02-28 2010-04-27 Akzo Nobel Nv Injectable water-in-oil emulsions
AU2002309508A1 (en) 2001-03-12 2002-09-24 L2 Diagnostics, Llc Compositions and methods comprising west nile virus polypeptides
US20030104008A1 (en) 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
AUPR472501A0 (en) 2001-05-02 2001-05-24 Council Of The Queensland Institute Of Medical Research, The Equine rhinitis a virus antigens
WO2003061555A2 (en) 2001-07-27 2003-07-31 Wyeth West nile vaccine
JP5164305B2 (ja) 2001-10-19 2013-03-21 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 動物におけるフラビウイルス感染を予防および治療する方法
DE60330708D1 (de) 2002-11-15 2010-02-04 Sanofi Pasteur Biologics Co Impfstoff gegen das west-nile-virus
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
US7585621B2 (en) 2003-09-09 2009-09-08 Idexx Laboratories, Inc. Detection of West Nile virus infection and vaccination
US7459163B2 (en) 2004-02-25 2008-12-02 University Of Kansas Infectious DNA as a vaccine against west nile and other flaviviruses
US7862829B2 (en) 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
US7482017B2 (en) 2004-09-09 2009-01-27 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
EP1645283A1 (en) 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Combination vaccine
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
BRPI0611581B1 (pt) 2005-06-24 2021-08-03 Intervet International B.V. Flavivírus quimérico inativado, composição imunogênica, e, vacina
US7384642B2 (en) 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
US7425336B2 (en) 2005-08-25 2008-09-16 Mevial Limited Canine influenza vaccines
CN101309701A (zh) 2005-10-07 2008-11-19 辉瑞产品公司 治疗犬流感的疫苗和方法
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
AU2006310555B2 (en) 2005-11-01 2011-08-04 Intervet International B.V. Prime boost vaccine for the protection of equines against equine influenza
US7455842B2 (en) 2005-12-05 2008-11-25 University Of Kansas Chimeric West Nile viruses and uses thereof
KR100850545B1 (ko) 2007-10-30 2008-08-05 주식회사 에니멀제네틱스 신규한 개 인플루엔자 바이러스 및 이의 백신
WO2010025469A1 (en) 2008-08-29 2010-03-04 Boehringer Ingelheim Vetmedica, Inc. West nile virus vaccine
EP2772266B1 (en) 2011-03-14 2019-07-31 Boehringer Ingelheim Animal Health USA Inc. Equine Rhinitis vaccine

Also Published As

Publication number Publication date
NZ708320A (en) 2016-08-26
EP2686012B1 (en) 2020-12-02
ES2748555T3 (es) 2020-03-17
BR122019023542B1 (pt) 2022-02-15
AU2012229192A1 (en) 2013-08-29
AU2012229192B2 (en) 2017-04-20
CA3018230A1 (en) 2012-09-20
US9187730B2 (en) 2015-11-17
EP2686012A2 (en) 2014-01-22
CA2829226A1 (en) 2012-09-20
EP2772266B1 (en) 2019-07-31
TW201300537A (zh) 2013-01-01
AU2017201526A1 (en) 2017-03-30
AU2017201526B2 (en) 2019-07-18
MA35303B1 (fr) 2014-08-01
EP2772266A1 (en) 2014-09-03
NZ614147A (en) 2015-08-28
AU2017201526C1 (en) 2019-10-24
CA2829226C (en) 2023-01-03
BR112013023354B1 (pt) 2022-02-15
MX2013010125A (es) 2013-10-07
WO2012125525A2 (en) 2012-09-20
ES2842595T3 (es) 2021-07-14
AR085800A1 (es) 2013-10-30
US20120237543A1 (en) 2012-09-20
WO2012125525A3 (en) 2013-02-28
MX350718B (es) 2017-09-14

Similar Documents

Publication Publication Date Title
IN2012DN02736A (pt)
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
TN2013000485A1 (en) 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
BR112014009866A2 (pt) formulações de anticorpos e métodos
MX341395B (es) Compuestos (lipopeptidos basados en cisteina) y composiciones como agonistas de tlr2 usados para el tratamiento de infecciones, inflamaciones, enfermedades respiratorias, etc.
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
BR112015001313A2 (pt) composições de vacina
MY168959A (en) Vaccine compositions for the prevention of dengue virus infection
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
MX2013012233A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
BR112015008417A2 (pt) composição imunogênica, e, vacina
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
BR112014002674A2 (pt) 3-(bifenil-3-il)-4-hidróxi-8-metóxi-1-azaspiro[4.5]dec-3-en-2-onas substituídas
BR112014002173A2 (pt) proteínas purificadas
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
BR112013028789A2 (pt) processo
BR112015002979B8 (pt) Forma cristalina, e, composição farmacêutica
BR112013023354A2 (pt) vacina para rinite equina
BR112014000889A2 (pt) tratamento para hipoxia
BR112013026868A2 (pt) intermediário para a síntese de caspofungina e método para o seu preparo
BR112014004737A2 (pt) composto de composição de cloridrato de ambroxol e método de preparação do composto
WO2014167582A3 (en) Vaccine composition for prophylaxis in ruminants

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)

B25G Requested change of headquarter approved

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/03/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.